Steven S.  Myers net worth and biography

Steven Myers Biography and Net Worth

Steven S. Myers joined the Caladrius Board in November 2006. He graduated from Stanford University with a B.S. in Mathematics. He is a four-time serial entrepreneur, an Ernst & Young “Entrepreneur of the Year” for Software and Information Services, and a recipient of the California Governor’s Special Recognition Award.  He has served as a board director of more than a dozen companies, public and private, and has conducted business in a dozen countries in Europe and Asia.

Mr. Myers is the founder, President and Director of his private equity investment company, Dolphin Capital Holdings, Inc., which invests in companies with innovative business strategies. Portfolio investments have included cyber security, applied materials development, regenerative medicine, biotechnology, medical devices, alternative energy, aircraft management, distressed debt, and for-income real estate. 

Mr. Myers founded SM&A, an Aerospace & Defense Industry management consulting firm that grew over a 25 year period to over $100 million in annual revenue and over 800 employees, spearheading industry-changing innovations in competing for and managing U.S. Government contracts. During his tenure the company managed more than $360 billion in major program competitions. After conducting a successful Nasdaq listed IPO in 1998, he served as Chairman and CEO of SM&A for another ten years. The company was sold to private equity in 2008. 

A US Government policy advisor on Cyber Security, he served in 2012 on the Department of Homeland Security Task Force on Cyber Security Resources and briefed then-DHS Secretary Napolitano on the Task Force recommendations. He served three terms on the US State Department Advisory Committee on International Economic Policy, which advises the US Secretary of State on foreign policy issues. At the Pacific Council on International Policy he serves on the Board of Directors and as Chairman of its National Security Member Committee.

An accomplished public speaker and published author, Mr. Myers is a nationally recognized thought leader on business competitiveness and is a frequent guest lecturer on entrepreneurship at the USC Marshall School of Business. He is a two-time U.S. Air Force Veteran, and a highly accomplished aviator with an Airline Transport Pilot license and twelve jet type ratings, including the Boeing 777. In 2020 he received the FAA’s highest civilian award, the Wright Brothers Master Pilot Award. 

The Caladrius Board has concluded that Mr. Myers should continue serving as a Director based upon his technical background and diverse entrepreneurial and business expertise, including his having established and managed innovative enterprises (in the areas of proposal development for competitive procurements, aircraft leasing and private equity investment), together with his technical experience in the aerospace and defense sector.

How do I contact Steven S. Myers?

The corporate mailing address for Mr. Myers and other Caladrius Biosciences executives is 110 ALLEN ROAD 2ND FLOOR, BASKING RIDGE NJ, 07920. Caladrius Biosciences can also be reached via phone at (908) 842-0100 and via email at [email protected]. Learn More on Steven S. Myers' contact information.

Has Steven S. Myers been buying or selling shares of Caladrius Biosciences?

Steven S. Myers has not been actively trading shares of Caladrius Biosciences during the past quarter. Most recently, on Wednesday, December 8th, Steven S. Myers bought 33,785 shares of Caladrius Biosciences stock. The stock was acquired at an average cost of $0.89 per share, with a total value of $30,068.65. Learn More on Steven S. Myers' trading history.

Steven S. Myers Insider Trading History at Caladrius Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/8/2021Buy33,785$0.89$30,068.65View SEC Filing Icon  
12/9/2014Buy20,000$3.56$71,200.00View SEC Filing Icon  
12/1/2014Buy10,000$3.92$39,200.00View SEC Filing Icon  
11/24/2014Buy19,800$3.94$78,012.00View SEC Filing Icon  
See Full Table

Steven S. Myers Buying and Selling Activity at Caladrius Biosciences

This chart shows Steven S Myers's buying and selling at Caladrius Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Caladrius Biosciences Company Overview

Caladrius Biosciences logo
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $6.37
Low: $0.43
High: $8.38

2 Week Range

Now: N/A

Volume

466,373 shs

Average Volume

522,308 shs

Market Capitalization

$26.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.91